ecancer

Establishing immunotherapy as a standard in cancer treatment

Prof Drew Pardoll – Johns Hopkins University School of Medicine, Baltimore, USA

18 Jul 2013

ECC 2013 Preview: Scientific programme highlights

Prof Vincenzo Valentini and Ian Banks

11 Jul 2013

Science behind phase I clinical trials: targeting tumour cell development pathways

Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA

6 Jun 2013

ASCO 2013 highlights

Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA

6 Jun 2013

The problem of unnecessary treatment of prostate cancer

Dr Rosalind Eeles - Royal Marsden Hospital, London, UK

3 Jun 2013

Racial disparities in cancer outcomes

Dr Camille Ragin - Fox Chase Cancer Center, Philadelphia, USA

19 Apr 2013

Vitamin D and cancer prevention

Dr Anna Woloszynska-Read

17 Apr 2013

ASCO GU: Current thinking in mCRPC

Dr Howard Scher - Memorial Sloan Kettering Cancer Center, New York

1 Mar 2013

Effect of therapeutic anticoagulation on overall survival in men receiving docetaxel for mCRPC

Dr Caroline Pratz - Kimmel Cancer Center, Johns Hopkins University, Baltimore

25 Feb 2013

Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer

Dr Bertrand Tombal - Catholic University of Louvain, Belgium

25 Feb 2013

Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up

Dr Andrew Loblaw - Sunnybrook Health Sciences Centre, Toronto, Canada

25 Feb 2013

Pelvic radiotherapy and androgen blockade for high risk prostate cancer

Dr Abdenour Nabid - Sherbrooke University, Quebec, Canada

25 Feb 2013

More from ecancer